Literature DB >> 32951318

Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States.

Chris LaVallee1,2, Karen L Rascati1, Tyler H Gums1.   

Abstract

Hypertension affects approximately one-third of the US adults. This study investigated antihypertensive utilization patterns among hypertensive patients who were prescribed treatment, yet still experienced uncontrolled hypertension. Data from the Decision Resources Group Real World Evidence Data Repository US database (2015-2016) were used to construct a cohort of uncontrolled hypertension patients to observe antihypertensive utilization patterns. Results for 5059 patients, with an average age of 57.8 (SD = 13.7), who had, on average 2.4 agents prescribed. Approximately half (51.9%) were female, and most were White (86.8%). More than one-third (N = 1877; 37.1%) of patients were diagnosed with diabetes mellitus (DM) or chronic kidney disease (CKD) that could independently contribute to increased cardiovascular complications. Overall, the most common treatments prescribed, as percent of agents and as percent of patients, respectively, were diuretics (24.9%; 59.6%), followed by angiotensin-converting enzyme inhibitors (ACEIs) (23.8%; 56.9%), beta-blockers (BBs) (18.7%; 44.8%), calcium channel blockers (CCBs) (15.4%; 36.8%), and angiotensin II receptor blockers (ARBs) (13.5%; 32.3%). Approximately one-tenth (10.5%) of the prescriptions were written for fixed-dose combination therapies. Among patients diagnosed with DM and CKD (N = 200), the order of the most common agents was the same as the overall cohort. Only 5.6% of prescriptions written for these patients were fixed-dose combination therapy. Based on clinical guidelines, which suggest using ACEIs, ARBs, or CCBs as first-line therapy, and fixed-dose combination therapy to increase adherence, this indicates over-prescribing of BBs and under-prescribing of fixed-dose combination therapy. These findings illustrate the need to further investigate challenges faced by patients and providers in treatment decision-making.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  antihypertensive therapy; clinical management of high blood pressure; diabetes; renal disease; resistant hypertension

Mesh:

Substances:

Year:  2020        PMID: 32951318      PMCID: PMC8029865          DOI: 10.1111/jch.14041

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  35 in total

1.  Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.

Authors:  Kenneth A Jamerson; Oliseyenum Nwose; Lisa Jean-Louis; Lesley Schofield; Das Purkayastha; Michelle Baron
Journal:  Am J Hypertens       Date:  2004-06       Impact factor: 2.689

Review 2.  Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease.

Authors:  Conal Daly
Journal:  Nephrol Dial Transplant       Date:  2007-09       Impact factor: 5.992

3.  Heart disease and stroke statistics--2015 update: a report from the American Heart Association.

Authors:  Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Joshua Z Willey; Daniel Woo; Robert W Yeh; Melanie B Turner
Journal:  Circulation       Date:  2014-12-17       Impact factor: 29.690

4.  Low medication adherence and the incidence of stroke symptoms among individuals with hypertension: the REGARDS study.

Authors:  Paul Muntner; Jewell H Halanych; Kristi Reynolds; Raegan Durant; Suma Vupputuri; Victor W Sung; James F Meschia; Virginia J Howard; Monika M Safford; Marie Krousel-Wood
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-04-22       Impact factor: 3.738

5.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

Review 6.  Diabetes and macrovascular disease.

Authors:  Aaron Vinik; Mark Flemmer
Journal:  J Diabetes Complications       Date:  2002 May-Jun       Impact factor: 2.852

7.  Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004.

Authors:  Dong-Churl Suh; Chul-Min Kim; In-Sun Choi; Craig A Plauschinat; Joseph A Barone
Journal:  J Hypertens       Date:  2009-09       Impact factor: 4.844

8.  KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999-2004.

Authors:  Jon J Snyder; Allan J Collins
Journal:  Am J Nephrol       Date:  2009-02-06       Impact factor: 3.754

9.  Relation of glycemic control to diabetic microvascular complications in diabetes mellitus.

Authors:  R Klein; B E Klein; S E Moss
Journal:  Ann Intern Med       Date:  1996-01-01       Impact factor: 25.391

10.  Improving blood pressure control rates: is there more we can do?

Authors:  George L Bakris; Matthew R Weir; Henry R Black
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-02       Impact factor: 3.738

View more
  2 in total

Review 1.  Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies.

Authors:  Mohamed Hassanein; Mousa A J Akbar; Mostafa Al-Shamiri; Ashraf Amir; Aslam Amod; Richard Chudleigh; Tarik Elhadd; Hussien Heshmat; Mahdi Jibani; Yousef M Al Saleh
Journal:  Diabetes Ther       Date:  2022-06-09       Impact factor: 3.595

2.  Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States.

Authors:  Chris LaVallee; Karen L Rascati; Tyler H Gums
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-20       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.